Chitosan is a potential inhibitor of ovarian cancer: Molecular aspects

Chamani, M. and Maleki Dana, P. and Chaichian, S. and Moazzami, B. and Asemi, Z. (2020) Chitosan is a potential inhibitor of ovarian cancer: Molecular aspects. IUBMB Life, 72 (4). pp. 687-697.

Full text not available from this repository.
Official URL:


Although ovarian cancer has a lower prevalence than breast cancer, its mortality rate is three times higher, which is reported to increase in the coming years. As the early stages of ovarian cancer do not have any obvious symptoms, in most of the cases, this cancer is diagnosed at advanced stages with a poor prognosis. Moreover, in many patients who are diagnosed with advanced stage, relapse of the disease and drug resistance are observed. Over the past years, these women have been treated with chemotherapy and cytoreductive surgeries. However, the chemotherapy could affect the healthy tissues in addition to the malignancies. Therefore, discovering new diagnostic and therapeutic options seems to be a crucial need. Unlike the common invasive and/or nonspecific treatments, nanomedicine is trying to find a new way for cancer imaging, diagnosis, and drug delivery method. Nanoparticles (NPs), which has recently drawn attention, can be used in order to reduce the toxicity and frequent dosing of drugs, tumor-specific delivery, and early diagnosis for malignancies. Chitosan as an NP and product of chitin deacetylation has multiple characteristics, including biocompatibility, biodegradability, and safety. In this review, we cover the studies concerned with the role of chitosan in finding solutions to overcome the problems faced in ovarian cancer treatments. Furthermore, we highlight how chitosan is being used in delivering chemotherapy drugs, gene therapy, and imaging methods for both detection and image-guided therapies. © 2019 International Union of Biochemistry and Molecular Biology

Item Type: Article
Additional Information: cited By 0
Uncontrolled Keywords: chitosan; DNA; RNA, A wave; cancer chemotherapy; cancer diagnosis; cancer gene therapy; cancer prevention; cancer therapy; diagnostic imaging; drug delivery system; health hazard; human; nanomedicine; nonhuman; ovary cancer; Review; risk factor
Subjects: WP Gynecology
QZ Pathology
Depositing User: eprints admin
Date Deposited: 13 Sep 2020 04:37
Last Modified: 13 Sep 2020 04:37

Actions (login required)

View Item View Item